Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression

Biochemical Pharmacology

Volumn 53, Issue 12, 1997, Pages 1855-1866

  Van Triest, Baukelien ^a   Pinedo, Herbert M ^a   Telleman, Frank ^a   Van Der Wilt, Clasina L ^a   Jansen, Gerrit ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Antifolates; Lung resistance protein; Multidrug resistance protein; P glycoprotein; Thymidylate synthase

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; DOXORUBICIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; LOMETREXOL; METHOTREXATE; NOLATREXED; RALTITREXED; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; ENZYME ASSAY; ENZYME KINETICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030845438     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)82448-3     Document Type: Article

References (63)

1. Borst P and Pinedo HM, Drug resistance. In: Oxford Textbook of Oncology. (Eds. M Peckham, HM Pinedo, U Veronesi), pp. 586-601. Oxford University Press, New York, 1995.
2. Peters GJ and Jansen G, Resistance to antimetabolites. In: Principles of Antineoplastic Drug Development and Pharmacology. (Eds. RL Schilsky, GA Milano, MJ Ratain), pp. 543-585. Marcel Dekker, New York, 1996.
3. Sirotnak FM, Determinants of resistance to antifolates: Biochemical phenotypes, their frequency of occurence and circumvention. NCI Monographs 5: 27-35, 1987.
4. Bertino JR, Ode to Methotrexate. J Clin Oncol 11: 5-14, 1993.
5. Broxterman HJ, Jansen G, Linn SC and Lankelma J, The impact of transport-associated resistance in anticancer chemotherapy. In: Drug Transport in Antimicrobial and Anticancer Chemotherapy (Eds. Georgopopdakou NH), pp. 21-61. Marcel Dekker, New York, 1995.
6. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
7. Broxterman HJ, Giaccone G and Lankelma J, Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opion Oncol 7: 532-540, 1995.
8. Pinedo HM and Giaccone G, P-glycoprotein - A marker of cancer-cell behavior. New Eng J Med 333: 1417-1419, 1995.
9. Pinedo HM and Peters GJ, Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
10. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Meijer S, Smid K and Pinedo HM, Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil, J Clin Oncol 12: 2035-2042, 1994.
11. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L and Danenberg PV, Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44: 4144-4150, 1984.
12. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM and Allegra CJ, Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989.
13. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51: 5579-5586, 1991.
14. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K and Wilson HR, Biochemical and cellular pharmacology of 1843U89, a novel Benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53: 810-818, 1993.
15. Jackson RC, Johnston AL, Shetty BV, Vamey MD, Webber S and Webber SE, Molecular design of thymidylate synthase inhibitors. Proc Am Ass Cancer Res 34: 566-567, 1993.
16. Webber SE, Bleckman TM, Attard J, Deal JG, Katlhardekar V, Welsh KM, Webber S, Janson CA, Matthews DA, Smith WW, Freer ST, Jordan SR, Bacquet RJ, Howland EF, Booth CLJ, Ward RW, Hermann SM, White J, Morse CA, Hilliard JA and Barlett CA, Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36: 733-746, 1993.
17. Jackman AL and Calvert AH, Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871-881, 1995.
18. Chu E, Drake JC, Koeller DM, Zinn S, Jamidow CA, Yeh GC and Allegra CJ, Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143, 1991.
19. Zhang ZG, Harstrick A and Rustum YM, Mechanisms of resistance to fluoropyrimidines, Sem Oncol 19 (suppl 3): 4-9, 1992.
20. Van der Valk P, Van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer GL, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pinedo HM and Scheper RJ, Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1: 56-64, 1990.
21. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J and Pinedo HM, Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35-41, 1990.
22. Flens MJ, Izqueirdo MA, Scheffer GL, Fritz JL, Meijer CJLM, Scheper RJ and Zaman GJR, Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 54: 4557-4563, 1994.
23. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM and Broxterman HJ, Functional detection of MDR/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72: 543-549, 1995.
24. Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P, The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
25. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistanc. Cancer Res 53: 1475-1479, 1993.
26. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC and Scheper RJ, The drug resistance-related protein LRP in the human major vault protein. Nature Med 1: 578-582, 1995.
27. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, Van der Valk P and Scheper RJ, Major vault protein LRP related multidrug resistance. Eur J Cancer 32A: 979-984, 1996.
28. Borst P, Genetic mechanisms of drug resistance. A review. Acta Oncol 30: 87-105, 1991.
29. Peters GJ, Laurensse E, Leyva A, Lankelma J and Pinedo HM, Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46: 20-28, 1986.
30. Bradford M, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
31. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WGEJ, Van Rijn J, Pinedo HM and Joenje H, Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49: 2988-2993, 1989.
32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bohesch H, Kenney S, Boyd MR, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 107-112, 1990.
33. Keepers YP, Pizao PE, Peters GJ, Van Ark-Otte J and Winograd B, Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
34. Spears CP, Gustavson BG and Frösing R, Folinic acid modulation of fluorouracil: Tissue kinetics of bolus administration. Invest New Drugs 7: 27-36, 1989.
35. Peters GJ, Van Groeningen CJ, Laurensse E and Pinedo HM, Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: Enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate. Eur J Cancer 27: 263-267, 1991.
36. Peters GJ, Laurensse E, Leyva A and Pinedo HM, Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer 23: 1869-1881, 1987.
37. Yalowich JC and Kalman TI, Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 34: 2319-2324, 1985.
38. Freemantle SJ, Aherne GW, Hardcastle A, Lunec J and Calvert AH, Increases in thymidylate synthase protein levels measured using newly developed antibodies. Proc Am Ass Cancer Res 32: 360, 1991.
39. Horikoshi T, Danenberg KD, Stadbauer THW, Volkenandt M, Shea LCC, Aigner K, Gustavsson B, Leichman L, Frösing R, Ray M, Gibson NW, Spears CP and Danenberg PV, Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52: 108-116, 1992.
40. Freemantle SJ, Jackman AL, Kelland LR, Calvert AH and Lunec J, Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer 71: 925-930, 1995.
41. Van der Wilt CL, Cloos J, De Jong M, Pinedo HM and Peters GJ, Screening of colon tumor cells and tissues for Folylpolyglutamate synthetase activity. Oncol Res 7: 317-321, 1995.
42. O'Connor BM, Rotundo RF, Nimec Z, McGuire JJ and Galivan J, Secretion (γ)-glutamyl hydrolase in vitro. Cancer Res 51: 3874-3881, 1991.
43. Braakhuis BJM, Jansen G, Noordhuis P, Kegel A and Peters GJ, Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 46: 2155-2161, 1993.
44. Van der Laan BFAM, Jansen G, Kathmann GAM, Westerhof GR, Schornagel JH and Hordijk GJ, In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int J Cancer 51: 909-914, 1992.
45. Vindelov LL and Christensen IJ, A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11: 753-770, 1990.
46. Fleming GF and Schilsky RL, Antifolates: The next generation. Sem Oncol 19: 707-719, 1992.
47. Keyomarsi K, Samet J, Molnar G and Pardee AB, The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 268: 15142-15149, 1993.
48. Assaraf YG, Molina A and Schimke RT, Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. J Nat Cancer Inst 81: 290-294, 1989.
49. Assaraf YG and Borgina MJ, Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype. Anti-Cancer Drugs 4: 395-406, 1993.
50. Washtien WL, Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol Pharmacol 21: 723-728, 1984.
51. Keyomarsi K and Moran RG, Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263: 14402-14409, 1988.
52. Chu E, Zinn S, Boarman D and Allegra CJ, Interaction of γ-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50: 5834-5840, 1990.
53. Van der Wilt CL, Pinedo HM, Smid K and Peters GJ, Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52: 4922-4928, 1992.
54. Pizzorno G, Sun Z and Handschumacher RE, Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem Pharmacol 49: 553-557, 1995.
55. Inaba M and Mithuhashi J, Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. Oncol Res 6: 303-309, 1994.
56. Chu E, Lai G-M, Zinn S and Allegra CJ, Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410-417, 1990.
57. Lin B-F and Shane B, Expression of Escherichia coli folylpolyglutamate synthetase in the chinese hamster ovary cell mitochondrion. J Biol Chem 269: 9705-9713, 1994.
58. Yao R, Rhee MS, Galivan J, Effects of γ-Glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells. Mol Pharmacol 48: 505-511, 1995.
59. Schlemmer SR and Sirotnak FM, Retentiveness of methotrexate polyglutamates in cultured L1210 cells; evidence against a role for mediated plasma membrane transport outward. Biochem Pharmocol 45: 1261-1266, 1993.
60. Jansen G, Westerhof GR, Jarmuszewski MJA, Kathmann IAM, Rijksen G and Schornagel JH, Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem 265: 18272-18277, 1990.
61. Westerhof GR, Schornagel JH, Kathmann IAM, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM and Jansen G, Carrier and receptor-mediated transport of folate antagonists targeting folate dependent enzymes: Correlates of molecular-structure and biological activity. Mol Pharmocol 48: 459-471, 1995.
62. Saxena M and Henderson GB, Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells. Biochem Pharmacol 51: 975-982, 1996.
63. De Graaf D, Sharma RC, Mechetner EB, Schimke RT and Roninson IB, P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93: 1238-1242, 1996.